Reproductive Endocrinology Practice Questions

Q: Which of the following statements is true regarding testicular feminization syndrome (androgen insensitivity syndrome)? a) Testes are present, b) Female habitus, c) XY genotype, d) Uterus present.

Presence of testes, female phenotype, and XY genotype.. ***Presence of testes, female phenotype, and XY genotype.*** - Testicular feminization syndrome, or **androgen insensitivity syndrome (AIS)**, is characterized by an **XY genotype** (chromosomal male) with a **female phenotype** due to the body's inability to respond to androgens. - Individuals with AIS possess **testes**, which produce androgens, but the target cells lack functional androgen receptors, leading to feminization. *Testes are present and XY genotype.* - While correct that **testes are present** and the genotype is **XY**, this option is incomplete as it doesn't mention the striking feature of the female phenotype. - The core of the syndrome is the discrepancy between the genetic sex and the external appearance, which is not fully captured. *Female phenotype with XY genotype.* - This statement is accurate regarding the **phenotype** and **genotype** but omits the presence of internal gonads (testes), which is a key diagnostic feature. - The presence of female external characteristics despite a male genotype is central to the diagnosis and understanding of AIS. *Presence of uterus and XY genotype.* - This statement is incorrect because individuals with complete androgen insensitivity syndrome **do not have a uterus**. - The **Müllerian inhibiting factor** produced by the testes during fetal development causes the regression of Müllerian ducts, preventing uterus formation.

Q: In Testicular Feminization syndrome, when is gonadectomy indicated?

At puberty. ***At puberty*** - Gonadectomy is recommended at puberty in individuals with **Androgen Insensitivity Syndrome (Testicular Feminization)** to minimize the risk of gonadal malignancy. - Delaying until puberty allows for the spontaneous development of **secondary sexual characteristics** (e.g., breast development) from endogenous estrogen produced by the testes. *Immediately after diagnosis* - Performing gonadectomy immediately would prevent the natural pubertal development and necessitate earlier **estrogen replacement therapy**. - The risk of **gonadal malignancy** is low before puberty in AIS. *Only if malignancy develops* - This approach is not recommended due to the increased risk of **gonadal tumors (gonadoblastoma, dysgerminoma)** associated with undescended testes in AIS, especially after puberty. - Prophylactic removal is preferred to avoid the development and potential spread of malignancy. *When signs of androgenization appear* - **Androgenization** (virilization) does not typically occur in complete AIS because the androgen receptors are *non-functional*, making the body unable to respond to androgens. - Therefore, waiting for signs of androgenization would not be relevant in managing complete AIS.

Q: All of the following features are similar in androgen insensitivity syndrome and Mullerian agenesis except:

Normal axillary hair. ***Normal axillary hair*** - In **androgen insensitivity syndrome (AIS)**, there is typically **sparse or absent pubic and axillary hair** due to the body's inability to respond to androgens, despite normal or elevated testosterone levels. - In **Müllerian agenesis (MRKH syndrome)**, ovarian function is normal with normal androgen production and response, resulting in **normal axillary and pubic hair development**. - This is the **key differentiating feature** between the two conditions. *Absent Mullerian duct* - Both conditions feature **absent or rudimentary Müllerian duct** derivative structures (uterus, fallopian tubes, upper vagina). - In AIS, this is due to **Müllerian-inhibiting substance (MIS)** produced by functional testes. In MRKH, it's due to congenital developmental failure of the Müllerian ducts. *Breast development* - Both conditions show **normal breast development**. - In AIS, breast development occurs due to peripheral **aromatization of testosterone to estrogen** (breast tissue does not require androgen receptors for estrogen response). - In MRKH, breast development is normal due to **normal ovarian estrogen production**. *Primary amenorrhea* - Both conditions present with **primary amenorrhea**, defined as absence of menstruation by age 15. - In AIS, amenorrhea occurs because the uterus is absent (Müllerian structures did not develop due to MIS from testes). - In MRKH, the uterus is absent or rudimentary due to Müllerian agenesis, despite having functional ovaries with normal cyclic hormonal changes.

Q: In a clinical scenario where a patient experiences withdrawal bleeding after continuous administration of progestins, which of the following factors is most likely responsible?

Estrogen concentration is sufficient. ***Estrogen concentration is sufficient*** - Withdrawal bleeding after progestin administration indicates that the endometrium has been adequately primed by **estrogen**. - Progestins induce secretory changes in the endometrium, and their subsequent withdrawal leads to shedding if sufficient estrogen has stimulated initial endometrial proliferation. *Structural abnormality in the pelvis* - **Structural abnormalities** like fibroids or polyps can cause abnormal uterine bleeding, but they do not typically explain withdrawal bleeding after progestin cessation. - These conditions would likely cause irregular bleeding patterns irrespective of hormonal manipulation. *Associated with endocrine disorder* - While endocrine disorders can cause **abnormal uterine bleeding**, withdrawal bleeding after progestin therapy suggests a hormonal response. - Endocrine disorders might be the underlying reason for initial anovulation, but the progestin challenge itself is a diagnostic tool to assess endometrial estrogenization. *Atrophic endometrium* - An **atrophic endometrium** would not typically bleed after progestin withdrawal because it lacks sufficient estrogen priming. - Withdrawal bleeding implies that there was an adequately proliferated endometrium to begin with, which is then transformed by progestins.

Q: The most characteristic clinical feature of androgen insensitivity syndrome (testicular feminization syndrome) is:

Normal breast development is observed. ***Normal breast development is observed*** - This is the **most characteristic clinical feature** of **androgen insensitivity syndrome (AIS)** that creates the striking paradox of the condition. - Individuals with AIS have normal or elevated levels of **testosterone**, which is aromatized to **estrogen**. - This **estrogen** promotes the development of **female secondary sexual characteristics**, including breast development. - The presence of **normal breast development in a genetic male (46,XY)** is the hallmark presentation that brings patients to medical attention. *Buccal smear shows no Barr bodies* - This statement is **factually true** - a buccal smear showing **no Barr bodies** indicates a **46,XY karyotype**, which is characteristic of AIS. - However, this is a **diagnostic test finding**, not the clinical presentation feature that defines the syndrome. - It helps confirm the diagnosis but is not the primary characteristic feature. *Menstruation is absent due to primary amenorrhea* - This statement is also **factually true** - **primary amenorrhea** is present in AIS. - Menstruation is absent because individuals with AIS **lack a uterus**, fallopian tubes, and ovaries due to **Müllerian inhibiting factor (MIF)** produced by Sertoli cells in the testes. - However, primary amenorrhea alone is non-specific and occurs in many conditions. *Testes are present but non-functional* - This statement is **incorrect** - while the **testes are present** (usually intra-abdominal or inguinal), they are **functionally active**. - They produce testosterone (which converts to estrogen) and Müllerian inhibiting factor. - The testes are functional in hormone production; the defect is in **androgen receptor insensitivity** in target tissues.

Question 1

Which of the following statements is true regarding testicular feminization syndrome (androgen insensitivity syndrome)? a) Testes are present, b) Female habitus, c) XY genotype, d) Uterus present.

Accepted Answer

Presence of testes, female phenotype, and XY genotype.

Answer

Female phenotype with XY genotype.

Answer

Testes are present and XY genotype.

Answer

Presence of uterus and XY genotype.

Question 2

In Testicular Feminization syndrome, when is gonadectomy indicated?

Accepted Answer

At puberty

Answer

Only if malignancy develops

Answer

When signs of androgenization appear

Answer

Immediately after diagnosis

Question 3

All of the following features are similar in androgen insensitivity syndrome and Mullerian agenesis except:

Accepted Answer

Normal axillary hair

Answer

Absent Mullerian duct

Answer

Breast development

Answer

Primary amenorrhea

Question 4

In a clinical scenario where a patient experiences withdrawal bleeding after continuous administration of progestins, which of the following factors is most likely responsible?

Accepted Answer

Estrogen concentration is sufficient

Answer

Structural abnormality in the pelvis

Answer

Associated with endocrine disorder

Answer

Atrophic endometrium

Question 5

The most characteristic clinical feature of androgen insensitivity syndrome (testicular feminization syndrome) is:

Accepted Answer

Normal breast development is observed

Answer

Buccal smear shows no Barr bodies

Answer

Menstruation is absent due to primary amenorrhea

Answer

Testes are present but non-functional

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?